Global Human Insulin Market: Market Segments: By Product (HI Drugs [HI Analogs, HI Biologics], HI Delivery Devices [Syringes, Pens, Pen Needles, and Pumps]); By Application (Type II Diabetes, Type I Diabetes, Gestational Diabetes & Prediabetes);and Region – Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030

Region:Global

Author(s):

Product Code:FG366

Download Sample Report download
Buy the Full ReportStarting from $3850
Published on

December 2020

Total pages

150

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $3850

About the Report

About the Report

Product Overview

Insulin controls the metabolism of fat and carbohydrates in the body. It is a peptide hormone that is secreted by the beta cells of the islets of Langerhans in the pancreas and helps control the metabolism of glucose. It allows the blood to absorb glucose from skeletal muscle cells and fat tissues. By increasing insulin protein with the aid of human insulin refers to synthetic insulin developed in laboratories. It is possible to administer human insulin orally or by insulin infusion systems. Syringes, injection needles, and insulin pumps are some common insulin infusion machines. In order to produce insulin on time and consistently, these machines are used. Compared to conventional human insulin, modern human insulin achieves successful outcomes. The dosages and length of modern human insulin differ from person to person, since the demand for insulin varies from person to person.

Market Highlights

Global Human Insulin Market is expected to project a notable CAGR of 8.12% in 2030.

Global Human Insulin Market to surpass USD 90.12 Billion by 2030 from USD 42.12 Billion in 2018 at a CAGR of 8.12% throughout the forecast period, i.e., 2019-30. The growth of the worldwide demand for human insulin is mainly due to the increasing prevalence of diabetes. Changes in lifestyles, rising levels of obesity as well as geriatric populations and insufficient healthcare facilities are factors leading to an increasing number of diabetic patients globally. The growth of this market has also been fueled by favorable government policies and technological advancements such as innovation in insulin pens. Moreover, rising R&D investment in drug research and production and increasing awareness of diabetes are also driving the growth of the market.

Global Human InsulinMarket: Segments

HI delivery devices segment to grow with the highest CAGR of 11.12% during 2019-30

Global Human InsulinMarket is segmented byproducts into HI drugs and delivery devices.The greater market share of 79.2% in 2018 was accounted by HI drugs segment and growth in this segment is due to the high diabetes prevalence, increased drug discovery and development activities in research and development (R&D), increased consumer demand for HI analogues, and an increase in the geriatric population. HI, medications are further categorized into analogs and biologics, while syringes, pens, pen needles, pumps, and others are further categorized into HI delivery systems. Pens are further categorized into two groups of pens: reusable and disposable.HI delivery devices is expected to be the faster-growing category, globally, advancing at a CAGR of 11.1% during the forecast period. This is due to the rising prevalence of diabetes in countries with a large number of diabetic patients, such as China and India, and the growing focus of insulin pen manufacturers. In addition, some of the other factors driving the growth of this product category are technical developments in pens and medical reimbursements offered in developed regions.

Type II DiabetesSegment to grow with the highest CAGR of 9.12% during 2019-30

Global Human Insulin Market is segmented by application into type II diabetes, type I diabetes, and gestational diabetes and prediabetes.The greater market share in 2018 was accounted by type II diabetes in the human insulin market, with a revenue contribution of $35.1 billion and is expected to be the fastest-growing application segment over the forecast period. This can be mainly attributed to the increase in the prevalence of type II diabetes. Type II diabetes is expected to be the fastest growing application area in this market, advancing at a CAGR of 9.1% during the forecast period which is attributed to the prevalence of type II diabetes is growing. Compared to 40 years ago, the recurrence rate of type 2 diabetes has multiplied. Therefore, the global overall incidence of diabetes and diabetes obesity is likely to increase the demand for insulin, which may drive the global insulin therapeutics market.

Global Human InsulinMarket:Market Dynamics

Drivers

Growing Diabetes Prevalence

The rise in diabetic patient numbers is not limited to developing countries but is also seen in emerging countries. The worldwide increasing prevalence of diabetes coupled with the rising obese population is the key factor driving the human insulin demand because of the shift in lifestyle. The advent of pen devices, as well as safety pen needles for efficient insulin delivery, are also the driving forces for the global demand for human insulin. This is due to the different benefits compared to other regular needles when administering insulin by safety pens. There are various opportunities in the human insulin industry, such as enforcing regulations against needlestick accidents, needle anxiety, and a rising understanding of the risk of bloodborne pathogen transmission.

Technological advancements in the field of human insulin delivery devices

The rising use of insulin administration delivery devices can be seen as a major trend in the HI industry. Technological developments in insulin delivery devices have triggered investments by different industry participants in the production of insulin delivery devices. In September 2016, for example, the U.S. Medtronic's MiniMed 670 G, the first closed-loop artificial pancreas hybrid device designed to control blood sugar levels and automatically modify basal insulin doses in patients with type I diabetes, has been approved by the Food and Drug Administration (USFDA). The R&D in the insulin segments is rising year-on-year, as researchers strive to bring out the best molecule for the use of patients, minimize maximum side effects and improve their effectiveness. As a result, the growing prevalence of obesity and diabetes worldwide is likely to increase considerable insulin demand, which could drive the global insulin therapeutics market.

Restrain

High implementation and maintenance cost

Nevertheless, rigid regulatory standards for product approval are limiting the development of the demand for human insulin. Moreover, the high cost of producing goods presents major challenges to market growth during the forecast period.

Global Human InsulinMarket: Regions

Global Human InsulinMarket is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC and MENA.

Global Human InsulinMarket in North America held the largest market share of 39.2% in the year 2018 due to the increased incidences of diabetes and a growing geriatric population. In terms of revenues, European countries such as Germany, France, and Italy are developing. The Asia Pacific, on the other hand, is expected to display strong growth during the forecast period. In the forecast period, favorable government initiatives coupled with growing R&D initiatives by large businesses are boosting the human insulin market in this region. Due to its economic affordability for patients, the conventional North American human insulin drug market is projected to expand during the forecast period. Humulin, led by Novolin, has the largest market share. The conventional North American human insulin drug market in the United States does not have generic rivals.

Competitive Landscape:

The Global Human Insulin market, which is highly competitive, consists of several major players such as B. Braun Melsungen AG; Becton, Dickinson and Company; hold a substantial market share in the Global Human Insulin market. Other players analyzed in this report are Eli Lilly and Company; Novo Nordisk A/S; Wockhardt Limited; Ypsomed AG; Medtronic PLC; and Gulf Pharmaceutical Industries (Julphar). among others

The key players are launching various products in the human insulin industry to increase their market share. For instance, in March 2018, Biocon Limited received marketing authorization approval from the European Union (EU) and the Therapeutic Goods Administration (TGA) of Australia for Semglee (biosimilar insulin glargine) prefilled disposable pen. Semglee, which is developed by Biocon Limited in collaboration with Mylan N.V., is a 100 units/mL 3 mL prefilled disposable pen for people with diabetes.

Global Human InsulinMarket is further segmented by region into:

  • North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
  • Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
  • Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
  • APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
  • MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA

Global Human Insulin Market: Key Players

  • B. Braun Melsungen AG
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • ALBIREO PHARMA, INC
  • BECTON, DICKINSON AND COMPANY
  • BIOCON LIMITED
  • Sanofi Aventis
  • WOCKHARDT LIMITED
  • JULPHAR
  • SOME HOLDING AG
  • ELI LILLY AND COMPANY
  • NOVO Nordisk A/S
  • ADOCIA
  • Tonghua Dongbao Pharmaceutical Co., LTD
  • GSK
  • Gulf Pharmaceutical Industries
  • Medtronic PLC
  • Oramed Pharmaceuticals, Inc
  • SemBioSys Genetics
  • Pfizer, Inc.
  • Merck & Co., Inc.

Global Human InsulinMarket report also contains analysis on:

Global Human InsulinMarket Segments:

By Product:

  • HI Drugs
    • HI analogs
      • Type
        • Long-acting
        • Rapid-acting
        • Premixed
      • Brand
    • Lantus
    • Levemir
    • NovoRapid/Novolog
    • Humalog
    • Novomix
    • Apidra
    • Others
  • HI biologics
    • Type
      • Intermediate/rapid-acting
      • Premixed
      • Short-acting
    • Brand
      • Humulin
      • Insuman
      • Others

By Delivery Devices:

  • Pens
    • Disposable
    • Reusable
  • Syringes
  • Pen needles
  • Pumps
  • Others

By Application:

  • Type I Diabetes
  • Gestational Diabetes and Prediabetes
  • Human InsulinMarketDynamics
  • Human InsulinMarketSize
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies Involved in the Market
  • Value Chain of the Market
  • Market Drivers and Restraints

 

 

Products

Table of Contents

Table of Contents

Market Segmentation

ByProduct:

  • HI Drugs
    • HI analogs
      • Type
        • Long-acting
        • Rapid-acting
        • Premixed
      • Brand
    • Lantus
    • Levemir
    • NovoRapid/Novolog
    • Humalog
    • Novomix
    • Apidra
    • Others
  • HI biologics
    • Type
      • Intermediate/rapid-acting
      • Premixed
      • Short-acting
    • Brand
      • Humulin
      • Insuman
      • Others

By Delivery Devices:

  • Pens
    • Disposable
    • Reusable
  • Syringes
  • Pen needles
  • Pumps
  • Others

By Application:

  • Type II Diabetes
  • Type I Diabetes
  • Gestational Diabetes and Prediabetes

By Region:

  • North America
  • Europe
  • Asia Pacific
  • LATAM
  • MEA

Key Players Mentioned in the Report

  • B. Braun Melsungen AG
  • ALBIREO PHARMA, INC
  • BECTON, DICKINSON AND COMPANY
  • BIOCON LIMITED
  • Sanofi Aventis
  • WOCKHARDT LIMITED
  • JULPHAR
  • SOME HOLDING AG
  • ELI LILLY AND COMPANY
  • NOVO Nordisk A/S
  • ADOCIA
  • TonghuaDongbao Pharmaceutical Co., LTD
  • GSK
  • Gulf Pharmaceutical Industries
  • Medtronic PLC
  • Oramed Pharmaceuticals, Inc
  • SemBioSys Genetics
  • Pfizer, Inc.
  • Merck & Co., Inc.

Contents          

  1. Executive Summary
  2. Global Human Insulin Market
    1. Product Overview
    2. Market Definition
    3. Segmentation
    4. Assumptions and Acronyms
  3. Research Methodology
    1. Research Objectives
    2. Primary Research
    3. Secondary Research
    4. Forecast Model
    5. Market Size Estimation
  4. Average Pricing Analysis
  5. Macro-Economic Indicators
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Opportunity
    4. Trends
  7. Correlation & Regression Analysis
    1. Correlation Matrix
    2. Regression Matrix
  8. Recent Development, Policies & Regulatory Landscape
  9. Risk Analysis
    1. Demand Risk Analysis
    2. Supply Risk Analysis
  10. Global Human InsulinMarketAnalysis
    1. Porters Five Forces
      1. Threat of New Entrants
      2. Bargaining Power of Suppliers
      3. Threat of Substitutes
      4. Rivalry
    2. PEST Analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
  11. Global Human Insulin Market
    1. Market Size & forecast, 2019A-2030F
      1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  12. Global Human Insulin Market: Market Segmentation
    1. By Regions
      1. North America:(U.S. and Canada)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Europe: (Brazil, Mexico, Argentina, Rest of Latin America)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Asia-Pacific: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      4. LATAM: (Brazil, South Africa, Saudi Arabia, U.A.E. and Other Countries)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      5. MEA: (Brazil, South Africa, Saudi Arabia, U.A.E. and Other Countries)
        • By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    2. By Product: Market Share (2020-2030F)
      1. HI Drugs,By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. HI Delivery Devices, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
    3. By Application: Market Share (2020-2030F)
      1. Type II Diabetes,By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      2. Type I Diabetes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
      3. Gestational Diabetes & Prediabetes,By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
  1. Company Profile

    1. B. Braun Melsungen AG.
      1. Company Overview
      2. Company Total Revenue (Financials)
      3. Market Potential
      4. Global Presence
      5. Key Performance Indicators
      6. SWOT Analysis
      7. Product Launch
    2. ALBIREO PHARMA, INC
    3. • BECTON, DICKINSON AND COMPANY
    4. • BIOCON LIMITED
    5. • Sanofi Aventis
    6. • WOCKHARDT LIMITED
    7. • JULPHAR
    8. • YPSOMED HOLDING AG
    9. • ELI LILLY AND COMPANY
    10. • NOVO Nordisk A/S
    11. • ADOCIA
    12. • TonghuaDongbao Pharmaceutical Co., LTD
    13. • GSK
    14. • Gulf Pharmaceutical Industries
    15. • Medtronic PLC
    16. • Oramed Pharmaceuticals, Inc
    17. • SemBioSys Genetics
    18. • Pfizer, Inc.
    19. • Merck & Co., Inc.
    20. Other Prominent Players
  2. Consultant Recommendation

**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022